The Chitinase 3 Like Protein 1 pipeline drugs market research report outlays comprehensive information on the Chitinase 3 Like Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Chitinase 3 Like Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Central Nervous System, and Musculoskeletal Disorders which include the indications Oncology, Lung Cancer, Asthma, Idiopathic Pulmonary Fibrosis, Alzheimer’s Disease, and Fibrosis. It also reviews key players involved in Chitinase 3 Like Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Chitinase 3 Like Protein 1 pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Chitinase 3 Like Protein 1 overview
Chitinase-3-like protein 1 is a carbohydrate-binding lectin with a preference for chitin. Has no chitinase activity. It may play a role in tissue remodeling and in the capacity of cells to respond to and cope with changes in their environment. It plays key a role in T-helper cell type 2 (Th2) inflammatory response and IL-13-induced inflammation, regulating allergen sensitization, inflammatory cell apoptosis, dendritic cell accumulation and M2 macrophage differentiation.
For a complete picture of Chitinase 3 Like Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
